vs
Side-by-side financial comparison of ANI PHARMACEUTICALS INC (ANIP) and COHEN & STEERS, INC. (CNS). Click either name above to swap in a different company.
ANI PHARMACEUTICALS INC is the larger business by last-quarter revenue ($247.1M vs $143.8M, roughly 1.7× COHEN & STEERS, INC.). COHEN & STEERS, INC. runs the higher net margin — 24.3% vs 11.1%, a 13.1% gap on every dollar of revenue. On growth, ANI PHARMACEUTICALS INC posted the faster year-over-year revenue change (29.6% vs 2.9%). ANI PHARMACEUTICALS INC produced more free cash flow last quarter ($29.1M vs $-126.4M). Over the past eight quarters, ANI PHARMACEUTICALS INC's revenue compounded faster (34.1% CAGR vs 8.3%).
ANI Pharmaceuticals Inc is a U.S.-based specialty pharmaceutical firm that develops, manufactures and sells generic and branded prescription drugs. Its key segments cover dermatology, oncology, CNS therapies and anti-infectives, primarily serving U.S. healthcare providers, retail pharmacies and institutional medical clients.
Cohen & Steers is an American investment management company. It focuses on investments in real estate securities via real estate investment trusts (REIT) and alternative income via preferred securities.
ANIP vs CNS — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $247.1M | $143.8M |
| Net Profit | $27.5M | $34.9M |
| Gross Margin | — | — |
| Operating Margin | 14.1% | 28.0% |
| Net Margin | 11.1% | 24.3% |
| Revenue YoY | 29.6% | 2.9% |
| Net Profit YoY | 367.5% | -23.9% |
| EPS (diluted) | $1.14 | $0.67 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $247.1M | $143.8M | ||
| Q3 25 | $227.8M | $141.7M | ||
| Q2 25 | $211.4M | $136.1M | ||
| Q1 25 | $197.1M | $134.5M | ||
| Q4 24 | $190.6M | $139.8M | ||
| Q3 24 | $148.3M | $133.2M | ||
| Q2 24 | $138.0M | $121.7M | ||
| Q1 24 | $137.4M | $122.7M |
| Q4 25 | $27.5M | $34.9M | ||
| Q3 25 | $26.6M | $41.7M | ||
| Q2 25 | $8.5M | $36.8M | ||
| Q1 25 | $15.7M | $39.8M | ||
| Q4 24 | $-10.3M | $45.8M | ||
| Q3 24 | $-24.2M | $39.7M | ||
| Q2 24 | $-2.3M | $31.8M | ||
| Q1 24 | $18.2M | $34.0M |
| Q4 25 | 14.1% | 28.0% | ||
| Q3 25 | 15.9% | 34.5% | ||
| Q2 25 | 6.6% | 31.8% | ||
| Q1 25 | 13.3% | 33.6% | ||
| Q4 24 | -2.3% | 35.3% | ||
| Q3 24 | -13.8% | 33.7% | ||
| Q2 24 | 3.7% | 31.5% | ||
| Q1 24 | 14.8% | 32.8% |
| Q4 25 | 11.1% | 24.3% | ||
| Q3 25 | 11.7% | 29.4% | ||
| Q2 25 | 4.0% | 27.1% | ||
| Q1 25 | 8.0% | 29.6% | ||
| Q4 24 | -5.4% | 32.8% | ||
| Q3 24 | -16.3% | 29.8% | ||
| Q2 24 | -1.7% | 26.1% | ||
| Q1 24 | 13.2% | 27.7% |
| Q4 25 | $1.14 | $0.67 | ||
| Q3 25 | $1.13 | $0.81 | ||
| Q2 25 | $0.36 | $0.72 | ||
| Q1 25 | $0.69 | $0.77 | ||
| Q4 24 | $-0.45 | $0.89 | ||
| Q3 24 | $-1.27 | $0.77 | ||
| Q2 24 | $-0.14 | $0.63 | ||
| Q1 24 | $0.82 | $0.68 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $285.6M | $145.5M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $540.7M | $562.0M |
| Total Assets | $1.4B | $876.7M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $285.6M | $145.5M | ||
| Q3 25 | $262.6M | $98.1M | ||
| Q2 25 | $217.8M | $95.4M | ||
| Q1 25 | $149.8M | $65.2M | ||
| Q4 24 | $144.9M | $183.0M | ||
| Q3 24 | $145.0M | $106.5M | ||
| Q2 24 | $240.1M | $122.0M | ||
| Q1 24 | $228.6M | $99.5M |
| Q4 25 | $540.7M | $562.0M | ||
| Q3 25 | $505.8M | $550.3M | ||
| Q2 25 | $436.8M | $528.5M | ||
| Q1 25 | $418.6M | $507.7M | ||
| Q4 24 | $403.7M | $511.7M | ||
| Q3 24 | $405.9M | $491.0M | ||
| Q2 24 | $455.8M | $463.2M | ||
| Q1 24 | $452.0M | $378.9M |
| Q4 25 | $1.4B | $876.7M | ||
| Q3 25 | $1.4B | $801.6M | ||
| Q2 25 | $1.3B | $751.0M | ||
| Q1 25 | $1.3B | $834.9M | ||
| Q4 24 | $1.3B | $812.4M | ||
| Q3 24 | $1.3B | $727.8M | ||
| Q2 24 | $920.8M | $784.1M | ||
| Q1 24 | $914.5M | $680.7M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $30.4M | $-120.4M |
| Free Cash FlowOCF − Capex | $29.1M | $-126.4M |
| FCF MarginFCF / Revenue | 11.8% | -87.9% |
| Capex IntensityCapex / Revenue | 0.5% | 4.2% |
| Cash ConversionOCF / Net Profit | 1.10× | -3.45× |
| TTM Free Cash FlowTrailing 4 quarters | $171.4M | $-253.6M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $30.4M | $-120.4M | ||
| Q3 25 | $44.1M | $55.1M | ||
| Q2 25 | $75.8M | $-67.6M | ||
| Q1 25 | $35.0M | $-108.9M | ||
| Q4 24 | $15.9M | $96.7M | ||
| Q3 24 | $12.5M | $25.6M | ||
| Q2 24 | $17.4M | $31.4M | ||
| Q1 24 | $18.3M | $4.9M |
| Q4 25 | $29.1M | $-126.4M | ||
| Q3 25 | $38.0M | $52.6M | ||
| Q2 25 | $71.8M | $-69.8M | ||
| Q1 25 | $32.5M | $-110.0M | ||
| Q4 24 | $13.5M | $85.0M | ||
| Q3 24 | $7.7M | $24.2M | ||
| Q2 24 | $13.0M | $27.1M | ||
| Q1 24 | $13.7M | $537.0K |
| Q4 25 | 11.8% | -87.9% | ||
| Q3 25 | 16.7% | 37.1% | ||
| Q2 25 | 34.0% | -51.3% | ||
| Q1 25 | 16.5% | -81.8% | ||
| Q4 24 | 7.1% | 60.8% | ||
| Q3 24 | 5.2% | 18.2% | ||
| Q2 24 | 9.4% | 22.3% | ||
| Q1 24 | 10.0% | 0.4% |
| Q4 25 | 0.5% | 4.2% | ||
| Q3 25 | 2.7% | 1.8% | ||
| Q2 25 | 1.9% | 1.6% | ||
| Q1 25 | 1.3% | 0.8% | ||
| Q4 24 | 1.3% | 8.3% | ||
| Q3 24 | 3.2% | 1.1% | ||
| Q2 24 | 3.2% | 3.5% | ||
| Q1 24 | 3.3% | 3.5% |
| Q4 25 | 1.10× | -3.45× | ||
| Q3 25 | 1.66× | 1.32× | ||
| Q2 25 | 8.87× | -1.84× | ||
| Q1 25 | 2.23× | -2.74× | ||
| Q4 24 | — | 2.11× | ||
| Q3 24 | — | 0.65× | ||
| Q2 24 | — | 0.99× | ||
| Q1 24 | 1.00× | 0.14× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ANIP
| Sales Of Cortrophin Gel | $111.4M | 45% |
| Sales Of Generic Pharmaceutical Products | $100.8M | 41% |
| Sales Of ILUVIEN And YUTIQ | $19.8M | 8% |
| Sales Of Established Brands | $12.3M | 5% |
| Unapproved Products | $6.5M | 3% |
| Sales Of Royalties And Other Pharmaceutical Services | $2.7M | 1% |
CNS
Segment breakdown not available.
